BioHarvest Q2 2026 revenue rose 3.8% to USD 8.8 million; IFRS net loss narrowed to USD 3.7 million, or USD 0.17 per share.
IFRS operating loss widened to USD 2.5 million; gross margin slipped 1 percentage point to 58%.
Non-IFRS adjusted EBITDA loss widened to USD 1.6 million, including USD 0.9 million in CDMO services.
Secured its first CDMO manufacturing and supply agreement backing a planned 20-ton fragrance program over two years; limited production could start in H1 2027.
Cut full-year CDMO revenue outlook to USD 4-5 million; lowered expected CDMO EBITDA loss to USD 1.5-2.5 million.
BHST•
